Related Experiment Videos
Differential diagnosis of solid adrenal masses using adrenocortical scintigraphy
L Dominguez-Gadea1, L Diez, C Bas
1Nuclear Medicine Service, Hospital Ramón y Cajal, Madrid, Spain.
Clinical Radiology
|November 1, 1994
Summary
Adrenal scintigraphy using 75-Se-selenomethylcholesterol helps differentiate benign from malignant adrenal masses. Increased radiocholesterol uptake indicates benign lesions, aiding diagnosis in patients with adrenal tumors.
Area of Science:
- Nuclear Medicine
- Radiology
- Endocrinology
Background:
- Adrenal masses are frequently discovered incidentally.
- Differentiating benign from malignant adrenal lesions is crucial for patient management.
- Functional imaging can provide valuable diagnostic information.
Purpose of the Study:
- To assess the diagnostic utility of adrenal scintigraphy with 75-Se-selenomethylcholesterol in characterizing adrenal masses.
- To correlate scintigraphic findings with the nature (benign/malignant) of adrenal lesions.
Main Methods:
- 42 patients with solid adrenal masses detected by computed tomography were studied.
- Adrenal scintigraphy with 75-Se-selenomethylcholesterol was performed.
- Uptake patterns (increased, normal, decreased) were analyzed and correlated with lesion characteristics.
Main Results:
- 18 lesions with increased radiocholesterol uptake were benign.
- 12 lesions with normal uptake were mostly small (<2 cm) and benign, with one exception.
- 20 lesions with decreased uptake included metastases and nonfunctional adrenal carcinomas.
Conclusions:
- Adrenocortical scintigraphy offers functional insights into adrenal masses.
- This imaging modality is valuable for distinguishing benign from malignant adrenal lesions.